• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

    12/15/22 7:00:00 AM ET
    $GERN
    $MRNA
    $PFE
    $RVMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GERN alert in real time by email

    Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ:GERN), vice president of oncology at Genentech (part of the Roche Group) and medical director at Pharmacia / SUGEN (acquired by Pfizer). Dr. Kelsey has had key roles in the development of many oncology therapeutics including Sutent®, Perjeta®, Kadcycla®, Erivedge® and imetelstat.

    "I'm delighted to welcome Steve to our Board," said David J. Earp, JD, PhD, Circle's president and CEO. "We expect to initiate IND-enabling studies in our lead program, an orally bioavailable cyclin A inhibitor, in 2023, and are building the clinical team that will support this program as it enters clinical development. In parallel, we are progressing our pipeline of other targeted oncology therapeutics. Steve has extensive experience in early oncology clinical development, including building successful development teams, and I look forward to working with him closely as Circle progresses to become a clinical-stage company."

    "Circle's macrocycle platform offers a new approach to important oncology targets that have proven refractory to other modalities, and I have been impressed by the quality of the pre-clinical work and the broad clinical potential of the company's lead cyclin A program," noted Dr. Kelsey. "I'm excited to join Circle's Board and to help the company bring its promising therapies to cancer patients."

    Dr. Kelsey received his medical degrees from the University of Birmingham in the UK and trained as a hematologic oncologist at Barts and The London Hospital where he was a clinician-scientist focused in leukemias and lymphomas.

    About Circle Pharma, Inc.

    Circle has developed a platform that combines structure-based rational drug design and advanced synthetic chemistry to develop first-in-class macrocycle therapeutics for challenging targets to address unmet clinical needs. Circle's technology facilitates the design and synthesis of intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular therapeutic targets, and can be delivered by multiple routes, including oral administration. Circle's macrocycle drug discovery & development platform is applicable across a wide range of serious diseases; the company is initially focusing its development efforts on intracellular protein-protein interactions that are key drivers in cancer. Its pipeline includes programs targeting cyclin proteins, including cyclins A, E and D, which are part of the regulatory machinery that controls progression of cells through the cell cycle. Inhibition of cyclin A was originally reported to be synthetic lethal to cancer cells that carry mutations causing dysregulation of the Rb pathway – such mutations are frequently found in small cell lung cancer. Circle has demonstrated that its cyclin A inhibitor program has the potential to cause significant tumor regression in multiple additional solid and hematologic cancers.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005026/en/

    Get the next $GERN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GERN
    $MRNA
    $PFE
    $RVMD

    CompanyDatePrice TargetRatingAnalyst
    Geron Corporation
    $GERN
    5/8/2025$1.50Sector Outperform → Sector Perform
    Scotiabank
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    Geron Corporation
    $GERN
    2/27/2025$3.50 → $2.00Buy → Neutral
    B. Riley Securities
    Geron Corporation
    $GERN
    2/26/2025Buy → Neutral
    H.C. Wainwright
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/29/2025$99.00 → $51.00Buy → Neutral
    Goldman
    Moderna Inc.
    $MRNA
    12/18/2024Buy → Hold
    Argus
    More analyst ratings

    $GERN
    $MRNA
    $PFE
    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

      Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod

      7/1/25 6:30:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

      Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines' clinical-stage RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldo

      6/30/25 8:00:00 AM ET
      $RVMD
      $SMMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

      REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (NASDAQ:SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines' clinical-stage RAS(ON) inhibitors, including the multi-selecti

      6/30/25 8:00:00 AM ET
      $RVMD
      $SMMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $GERN
    $MRNA
    $PFE
    $RVMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 25, 2024 - FDA Roundup: October 25, 2024

      For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

      10/25/24 2:48:21 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for HYMPAVZI issued to PFIZER INC

      Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

      10/15/24 2:57:27 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

      For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

      10/11/24 2:12:15 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Taraporevala Cyrus

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:39:02 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith James C

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:38:59 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Narayen Shantanu

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:38:52 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Geron downgraded by Scotiabank with a new price target

      Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50

      5/8/25 8:26:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Moderna with a new price target

      Citigroup initiated coverage of Moderna with a rating of Neutral and set a new price target of $40.00

      3/13/25 8:15:14 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    SEC Filings

    See more
    • SEC Form S-8 filed by Geron Corporation

      S-8 - GERON CORP (0000886744) (Filer)

      6/30/25 5:04:21 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Revolution Medicines Inc.

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      6/27/25 4:05:55 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      6/24/25 7:05:20 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lawlis V Bryan bought $15,667 worth of shares (13,300 units at $1.18) (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      5/13/25 4:20:43 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Financials

    Live finance-specific insights

    See more
    • Pfizer Declares Third-Quarter 2025 Dividend

      Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery,

      6/25/25 5:30:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confere

      6/25/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

      6/2/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations

    $GERN
    $MRNA
    $PFE
    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 5:46:12 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 9:31:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Geron Corporation

      SC 13G - GERON CORP (0000886744) (Subject)

      11/14/24 6:25:29 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care